Intraocular Pressure Changes in the Contralateral Eye After Topical Treatment: Does an "Ophthalmotonic Consensual Reaction" Exist?

Hadas Newman MD, Shimon Kurtz MD and Robert David MD

Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

ABSTRACT: Background: The existence of "ophthalmotonic consensual reaction," a contralateral change in intraocular pressure in the fellow eye induced by treatment of the first eye only, was suggested in 1924. Since then, the validity of this mechanism has been controversial.

Objectives: To assess intraocular pressure changes in the contralateral fellow eyes of patients treated with IOP-lowering medication in one eye, and investigate the existence of an ophthalmotonic consensual reaction.

Methods: The study population included 38 patients with newly diagnosed bilateral ocular hypertension or early open angle glaucoma. One eye of each patient was randomly treated with one of five compounds: prostaglandin analogues, beta-blockers, alpha-2 agonists, carbonic anhidrase inhibitors and a combination therapy: dorzolamide hydrochloride–timolol maleate (Cosopt®, Merck Sharpe & Dohme). The eye with the higher baseline IOP was selected to be the treated eye. After 3 weeks a masked examiner measured the IOP in both the treated and untreated eye.

Results: Mean IOP of the treated eyes at baseline was 26.1 ± 4.2 mmHg and at follow-up 20.2 ± 2.9 mmHg, a reduction of IOP from baseline of -6 ± 3.8 mmHg, a mean percent reduction of -22 ± 10.1%. In the contralateral eyes, the mean IOP at baseline was 24.2 ± 3 mmHg and 23.1 ± 3.1 mmHg at follow-up; IOP reduction from baseline was -1.2 ± 1.8 mmHg, or mean percent reduction -4.7 ± 7.1%. A major contralateral IOP decrease was seen only in the beta-blockers and the combination (Cosopt®) treatment groups (-6.1 ± 8.3% and -12.3 ± 8.3% mean percent reduction, respectively, P < 0.05). The contralateral eyes in the prostaglandin analogues, CAI or α2-agonist groups showed only a small change in IOP (2.6 ± 4.6%, -3.2 ± 2.6%, +0.7 ± 3.3%, mean percent reduction, respectively, P < 0.05).

Conclusions: The existence of an ophthalmotonic consensual reaction was not supported.

KEY WORDS: contralateral fellow eye, intraocular pressure, ophthalmotonic consensual reaction

In 1924 Weekers [1] was the first to describe an "ophthalmotonic consensual reaction," a change in intraocular pressure in the contralateral eye induced by treatment of one eye. A decrease in IOP in the fellow eye has since been reported after ocular compression, tonography, trauma, cataract surgery of the sclera, paracentesis, laser trabeculoplasty and trabeculectomy [2-7]. It is also known that beta-blockers, when instilled unilaterally, reduce the IOP in the contralateral eye. The most widely accepted theory for their contralateral effect is systemic absorption, primarily through the nasolacrimal mucosa [8].

To the best of our knowledge, there has not been a prospective randomized clinical trial to investigate the hypothesis of a centrally controlled mechanism of pharmacologically induced IOP reduction. The purpose of the present study was to assess IOP changes in the contralateral fellow eyes after 3 weeks of treatment with different classes of topically administered IOP-lowering medications. The hypothesis was that if an OCR indeed exists, a contralateral IOP decrease could be detected in all untreated fellow eyes, regardless of the type of IOP-lowering treatment instilled.

PATIENTS AND METHODS

We enrolled 38 consecutive patients with newly diagnosed bilateral ocular hypertension or early open angle glaucoma. The research was conducted at the Tel Aviv Sourasky Medical Center and approved by its Ethics Committee and in accordance with the Helsinki Declaration. Inclusion criteria were patients naïve to any IOP-lowering treatment, age over 18 and IOP > 22 mmHg in both eyes. All persons gave their informed consent prior to their inclusion in the study.

We selected one eye of each patient to be treated randomly with one of five agents, IOP-lowering eye drops (prostaglandin analogues, β-blockers, α2-agonists, carbonic anhidrase inhibitors, and the dorzolamide hydrochloride–timolol maleate combination (Cosopt®, Merck Sharpe & Dohme, USA). All medications were administered according to their respective labeling. The eye with the higher baseline IOP was selected to be the treated eye. After 3 weeks a masked examiner measured the IOP in both the treated and untreated eye.

IOP = intraocular pressure
CAI = carbonic anhidrase inhibitors
OCR = ophthalmotonic consensual reaction
intraocular pressure was selected to be the treated eye. After 3 weeks of treatment, the same independent masked examiner measured the IOP in both the treated and untreated eye using Goldmann applanation tonometry. All efforts were made for the baseline and follow-up IOP measurement to be performed at about the same time of day.

Statistical analysis was performed using paired Student’s t-test, with a P value ≤ 0.05 considered to be statistically significant.

RESULTS

Thirty-eight patients were included, 19 males and 19 females. The treated eye was randomized to one of five types of IOP-lowering medication. Nine patients were treated with prostaglandin analogs (latanoprost, bimatoprost or travoprost), 11 with β-blockers (timolol 0.5% or timolol 0.1% gel), and 6 each with topical CAI (dorzolamide), α2-agonists (brimonidine tartrate 0.2%, Alphagan®, Allergan, USA) and the β-blocker/CAI combination (Cosopt®).

The right eye was treated in 27 of the 38 patients and the left eye in 11. Mean IOP of all the treated eyes at baseline was 26.1 ± 4.2 mmHg and at follow-up 20.2 ± 2.9 mmHg; the mean percent IOP reduction of -19.7 ± 10.7% in the treated eye had a mean reduction of -1.5 ± 2.1 mmHg or -6.1 ± 8.3% from baseline.

In the contralateral untreated eye, the mean IOP was 24.2 ± 3 mmHg at baseline and 23.1 ± 3.1 mmHg at follow-up; IOP reduction from baseline was -1.2 ± 1.8 mmHg, or mean percent reduction -4.7 ± 7.1%.

Table 1 shows the mean reduction in IOP from baseline (mmHg, percent) in each group of topical treatment (in treated and untreated fellow eyes). In the prostaglandin group, treated eyes had a mean reduction from baseline of -7.3 ± 1.9 mmHg, or mean percent reduction -26.7 ± 8.2%. The contralateral eye had a mean reduction of -4.9 ± 2.3 mmHg or -18.9 ± 9.3%.

The untreated contralateral eye had a mean reduction from each medication group baseline between treated and fellow eyes in each medication group. In the prostaglandin group, treated eyes had a mean reduction of -7.3 ± 1.9 mmHg, or mean percent reduction -26.7 ± 8.2%.

Table 1: IOP parameters in treated and fellow eyes, according to medication type

<table>
<thead>
<tr>
<th>Medication type</th>
<th>N (%) *</th>
<th>Eye</th>
<th>Baseline mean IOP</th>
<th>Follow-up mean IOP</th>
<th>Mean IOP reduction (mmHg)</th>
<th>Mean IOP reduction (%)</th>
<th>P value **</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prostaglandin</td>
<td>(23.7)</td>
<td>Treated</td>
<td>27.9±2.8</td>
<td>20.6±3.8</td>
<td>-7.3±1.9</td>
<td>-26.7±8.2</td>
<td>0.004</td>
</tr>
<tr>
<td>β-blockers</td>
<td>(28.9)</td>
<td>Treated</td>
<td>26.1±1.4</td>
<td>21.2±2.9</td>
<td>-4.9±2.3</td>
<td>-18.9±3.3</td>
<td>0.001</td>
</tr>
<tr>
<td>Combination</td>
<td>(15.8)</td>
<td>Treated</td>
<td>39.7</td>
<td>19.7±2.9</td>
<td>-10.3±6.6</td>
<td>-32.6±12.7</td>
<td>0.031</td>
</tr>
<tr>
<td>CAI</td>
<td>(15.8)</td>
<td>Treated</td>
<td>21.2±2.8</td>
<td>18.5±2.5</td>
<td>-2.7±0.5</td>
<td>-12.6±2.1</td>
<td>0.031</td>
</tr>
<tr>
<td>α2-agonist</td>
<td>(15.8)</td>
<td>Treated</td>
<td>24.7±1.4</td>
<td>19.9±1.9</td>
<td>-4.8±0.7</td>
<td>-19.5±2.4</td>
<td>0.031</td>
</tr>
</tbody>
</table>

* Number of patients in each medication group, with percent of patients from the total number of patients (n=38).

** P value after comparing mean IOP reduction (%) in treated eyes vs. fellow eyes in each medication group.

DISCUSSION

In 1924 Weekers described an “ophthalmotonic consensual reaction” – a change in intraocular pressure in the contralateral eye [1]. Following the original report, a reduction in IOP in the contralateral eye was reported after ocular compression,
tonography, trauma, cataract extraction of the sclera, paracentesis, laser trabeculoplasty and trabeculectomy [2-7].

The purpose of our study was to validate if indeed a central control mechanism or an "ophthalmotonic consensual reaction" of IOP really exists. The hypothesis was that if an OCR exists, a contralateral IOP decrease in all fellow untreated eyes occurs. Our results could not confirm the existence of a central or consensual control of the IOP. A major contralateral IOP decrease was seen only in the β-blockers and combination group (Cosopt®) (-6.1 ± 8.3% and -12.3 ± 8.3% respectively, mean percent reduction, P < 0.05). The other contralateral eyes in the prostaglandin analogues, CAI or α2-agonist groups showed only a small change in IOP (-2.6 ± 4.6%, -3.2 ± 2.6%, +0.7% ± 3.3%, mean percent reduction, respectively, P < 0.05).

The IOP changes in contralateral eyes have been noted in many studies. Cox et al. [9] described a contralateral IOP rise in animal eyes after unilateral optic nerve sections. They suggested a supraoptic nuclear control mechanism of IOP. Diestelhorst and Kriegstein [10] found an increase in postoperative aqueous humor flow in the unoperated eye 5 days after trabeculectomy in one eye. They suggested that filtration surgery in one eye triggers a central nervous system-mediated reflexive increase in aqueous flow to maintain physiologic stability in the anterior chamber of the operated eye. This response reflected an ocular–CNS reflex. However, they found no statistically significant change in the IOP in the unoperated eye, meaning that increase outflow was sufficient to compensate for the increase in inflow. Vysniauskiené and co-authors [2] studied 24 patients who underwent trabeculectomy with mitomycin-C. They found an IOP reduction in the contralateral eye one month post-surgery, which suggests the existence of an OCR. Mean IOP in all contralateral eyes decreased from 15.5 ± 5.5 mmHg to 13 ± 4.7 mmHg. In contrast, Yarangumeli et al. [11] reported an increase in IOP in contralateral eyes in a third of the patients after trabeculectomy with mitomycin-C. They found an IOP reduction in the contralateral eye (-1.2 ± 0.6 mmHg) and in aqueous humor flow in the operated eye, compared to 0.5% drops, but this suggestion was not confirmed in our study.

In 21 patients, brimonidine was found to have a slight contralateral IOP decrease in IOP (1.2 ± 0.6 mmHg) and in aqueous flow (12%) on day 8 of treatment [20]. In another study with 29 patients receiving brimonidine in one eye, there was a slight but significant reduction in IOP in the contralateral eye [21]. Our study found that in the α2-agonists group there was a similar effect on IOP in our study (-19.7 ± 10.7% in timolol 0.1% gel, and -18 ± 8.5% in timolol 0.5% solution), which is similar to the data found in the literature [19].

In 21 patients, brimonidine was found to have a slight contralateral IOP decrease in IOP (1.2 ± 0.6 mmHg) and in aqueous flow (12%) on day 8 of treatment [20]. In another study with 29 patients receiving brimonidine in one eye, there was a slight but significant reduction in IOP in the contralateral eye [21]. Our study found that in the α2-agonists group there was a small IOP increase in the contralateral eye (+0.7 ± 3.3%, P < 0.05).

Prostaglandin analogues are not known to have a crossover effect. Studies with latanoprost have not found a contralateral effect [22]. Our study noted a small reduction of IOP in the prostaglandin analogues and CAI group (-2.6 ± 4.6%, -3.2 ± 2.6%, P < 0.05).

We acknowledge that this study included only 38 patients, so the results should be interpreted with caution. A larger number of patients need to be evaluated in order to confirm our results. In summary, our study found a major contralateral IOP reduction only in the β-blockers and combination (Cosopt®) group. This effect is probably primarily due to

CNS = central nervous system

OHTS = Ocular Hypertension Treatment Study

**Centralized IOP Reduction**

A contralateral IOP reduction following topical β-blockers has been shown in numerous studies both in normal [13-15] and hypertensive eyes [12,14,16-18]. Overall, the contralateral effect is smaller in normotensive eyes than in hypertensive eyes [8]; however, there is great variability of results in both groups. The most widely accepted theory for their contralateral effect is systemic absorption, primarily through the nasolacrimal mucosa, resulting in transport of the β-blocker to the contralateral eye. Systemic absorption may also result in centrally mediated effects on IOP control in the contralateral eye. Other suggested mechanisms are contamination of the untreated eye and also OCR [8].

The Ocular Hypertension Treatment Study [8] is the largest study group available for evaluating the magnitude of the contralateral effect of topical β-blockers. In the OHTS, 817 patients received topical β-blockers in one eye. Mean reduction in IOP in the treated eyes was 5.9 ± 3.4 mmHg (22 ± 12%). Mean IOP reduction in the contralateral untreated eyes was 1.5 ± 3 mmHg (5.8 ± 12%) [8]. Our study demonstrates similar results: eyes treated with β-blockers had a mean percent reduction of -18.9 ± 9.3% in IOP, and the contralateral eyes -6.1 ± 8.3% (P < 0.05).

In the OHTS, factors associated with the magnitude of contralateral effect were the degree of IOP reduction in the treated eye and baseline IOP of the contralateral eye [8]. It is interesting to mention that our study found a similar contralateral decrease of IOP in both timolol 0.1% gel and 0.5% solution: -5.8 ± 10.2% (P = 0.063) and -6.4 ± 6.6% (P < 0.05), respectively. It is known that plasma levels of timolol 0.1% gel are significantly lower than those of timolol 0.5% drops [19], and thus the risk of systemic side effects is lower. We therefore could expect a lower contralateral IOP decrease in the 0.1% timolol gel compared to 0.5% drops, but this suggestion was not confirmed in our study. In the treated eyes, both drugs had a similar effect on IOP in our study (-19.7 ± 10.7% in timolol 0.1% gel, and -18 ± 8.5% in timolol 0.5% solution), which is similar to the data found in the literature [19].

In 21 patients, brimonidine was found to have a slight contralateral IOP decrease in IOP (1.2 ± 0.6 mmHg) and in aqueous flow (12%) on day 8 of treatment [20]. In another study with 29 patients receiving brimonidine in one eye, there was a slight but significant reduction in IOP in the contralateral eye [21]. Our study found that in the α2-agonists group there was a small IOP increase in the contralateral eye (+0.7 ± 3.3%, P < 0.05).

Prostaglandin analogues are not known to have a crossover effect. Studies with latanoprost have not found a contralateral effect [22]. Our study noted a small reduction of IOP in the prostaglandin analogues and CAI group (-2.6 ± 4.6%, -3.2 ± 2.6%, P < 0.05).

We acknowledge that this study included only 38 patients, so the results should be interpreted with caution. A larger number of patients need to be evaluated in order to confirm our results. In summary, our study found a major contralateral IOP reduction only in the β-blockers and combination (Cosopt®) groups. This effect is probably primarily due to
the known systemic absorption of β-antagonists and not due to an “ophthalmotonic consensual reaction,” as this effect was not encountered in the contralateral eyes in the groups treated with prostaglandin, CAI or α2-agonists.

Corresponding author:
Dr. H. Newman
Dept. of Ophthalmology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv 64239, Israel
Phone: (972-3) 697-3868
Fax: (972-3) 697-3867
e-mail: hadasng@gmail.com

References
19. Rouland JE, Morel-Mandrino P, Elena PP, Polzer H, Sunder Raj P. Timolol 0.1% gel (Nyongel 0.1%) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica 2002; 216: 449-54.

Capsule
The proapoptotic protein Puma active against cancer

One reason cancer cells are so tenacious is that they have often lost the normal apoptotic regulators that would trigger cell death. Thus, treatments that reduce apoptosis would be expected to promote tumorigenesis. Surprisingly, Labi et al. and Michalak et al. (Genes Dev 2010; 24: 1602, 1608) found that mice made deficient in the proapoptotic protein Puma showed a lower incidence of lymphoma after exposure to ionizing radiation. Independently, the authors concluded that the explanation has to do with the effects of radiation on hematopoietic stem cells and their contribution to cancer. When normal animals were exposed to radiation, cells in the bone marrow or thymus died, which stimulated their replenishment through proliferation of hematopoietic stem cells. Multiple rounds of radiation made these animals more likely to develop DNA damage associated with excessive cell division, and this led to tumor formation. On the other hand, mice missing Puma exhibited diminished cell death in response to radiation, and hence suffered less replication stress on their hematopoietic stem cells. These results may have implications for cancer patients who undergo similar rounds of γ-irradiation or for therapeutic strategies using agents that act like Puma to stimulate cell death: either treatment might have the potential to promote formation of a secondary cancer.

Eitan Israeli

“Truth, in matters of religion, is simply the opinion that has survived”

Oscar Wilde (1854-1900), Irish writer and poet. Flamboyant compared to the typical Victorian styles of the time, he was considered decadent and was the target of moral outrage in Europe and America. He was part of the ever-growing movement of ‘decadents’ who advocated pacifism, social reform, and libertarianism. While many vilified him, he was making his mark with style and wit and his plays were very successful.